Sandra Brafford, MD
Hospitalist · Tallahassee, FLNPI 1386846517
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 131 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 22.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $704 and has fallen 80.9% since, to $135 in 2025. Among hospitalist clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 131 payments — averaging $18.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$545
- Pfizer$430
- Amgen$307
- Novartis$286
- Johnson & Johnson$161
- E.r. Squibb & Sons, L.L.C.$130
- plus $548 from 13 others
What the payments were for
- Food & beverage$2,407100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 22 | $545 |
| Pfizer | 40 | $430 |
| Amgen(2 entities) | 10 | $307 |
| Novartis | 15 | $286 |
| Johnson & Johnson | 11 | $161 |
| E.r. Squibb & Sons, L.L.C. | 6 | $130 |
| Boehringer Ingelheim | 5 | $104 |
| Mylan Specialty L.p. | 5 | $102 |
| Merck | 4 | $82 |
| AstraZeneca | 2 | $48 |
| Gilead | 1 | $34 |
| Exact Sciences | 2 | $34 |
| Cvrx, Inc. | 2 | $32 |
| Shionogi Inc | 1 | $22 |
| Vifor Pharma, Inc. | 1 | $21 |
| Global Blood Therapeutics, Inc. | 1 | $20 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $18 |
| Smith+Nephew | 1 | $17 |
| Portola Pharmaceuticals, LLC | 1 | $15 |
How this compares
$2,407 in reported general payments places this provider in the 95th percentile of 1,570 hospitalist providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Atorvastatin Calcium | 15 | $141 |
| Carvedilol | 12 | $47 |
Paid to pharmacies, not to this prescriber.
Other hospitalist in Tallahassee
- Nicky NelsonTallahassee$4K
- Roman BalsysTallahassee$4K
- Mark WheelerTallahassee$4K
- Heemanshi ShahTallahassee$2K
- Murray EpsteinMiami$370K
- Oliver AbelaFort Myers$77K
- Joshua LenchusFort Lauderdale$73K
- Tuncay TaskesenThe Villages$22K
- Diego MunozApopka$17K
- Francisco Perez LoretoMiami$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.